2-phenoxymethyl-4,5-dihydro-1H-imidazole | 43111-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-phenoxymethyl-4,5-dihydro-1H-imidazole
• 英文别名: 2-Phenoxymethyl-4,5-dihydro-1H-imidazol；2-(phenoxymethyl)-2-imidazoline；1H-Imidazole, 4,5-dihydro-2-(phenoxymethyl)-；2-(phenoxymethyl)-4,5-dihydro-1H-imidazole
• CAS: 43111-36-0
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: GRMJZZBFHKTYDJ-UHFFFAOYSA-N

物化性质

• 熔点：
  69-70 °C
• 沸点：
  364.4±25.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  33.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 2-phenoxymethyl-4,5-dihydro-1H-imidazole 在 甲酸 作用下， 以74%的产率得到1-methyl-2-(phenoxymethyl)-4,5-dihydroimidazole
  参考文献：
  名称：

  咪唑啉受体：定性的构效关系以及曲西唑啉和苯并唑啉的发现。具有高亲和力和前所未有的选择性的两个配体。

  摘要：

  观察到所有表征咪唑啉（I）受体的尝试都是使用非选择性或选择性差的配体进行的，这促使我们进行了旨在开发选择性配体的研究。在以前的研究中，以环丙唑啉I为起点，环丙唑啉I是一种也与I受体结合的有效的α1-肾上腺素能受体激动剂，我们发现环丙基环（2）的去除保留了对I2受体的高亲和力，同时降低了α1-肾上腺素激动剂活性。但是，人们认为这种残留的α1肾上腺素激动剂活性虽然适度，但可能会降低化合物2的效用，我们现在报告我们在这一领域的不断努力。从化合物2开始，我们首先通过等位置换消除了α1-激动剂成分，然后，通过对化合物7的构象限制，成功发现了曲西唑啉（9）和苯并唑啉（12）。这两个新的配体具有高亲和力（分别为pKi值8.74和9.07），并且对alpha 2-（I2 / alpha 2 7,762和18,621）和alpha 1-（I2 / alpha 1 2,344和2,691）肾上腺素能受体具有前

  DOI：

  10.1016/s0968-0896(97)00009-6
• 作为产物：
  描述：

  2-苯氧基乙腈 在 乙醇 作用下， 生成 2-phenoxymethyl-4,5-dihydro-1H-imidazole
  参考文献：
  名称：

  芳氧基乙am和2-（芳氧基甲基）-咪唑啉。

  摘要：

  DOI：

  10.1021/ja01199a036

文献信息

• 2-IMIDAZOLINES
  申请人：Galley Guido

  公开号：US20090018180A1

  公开（公告）日：2009-01-15

  The present invention relates to compounds of formula I wherein X—Y, R 1 , and n are as defined herein and to their pharmaceutically active salts. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X—Y、R1和n如本文所定义，并且涉及它们的药用活性盐。式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1，适用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• [EN] IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS<br/>[FR] LIGANDS DU RÉCEPTEUR AUX IMIDAZOLINES DE TYPE 1 À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：RIDEOUT DARRYL

  公开号：WO2016105448A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了作为止痛剂和用于治疗各种病症的化合物和组合物，如疼痛、头痛、触痛和纤维肌痛。本公开还提供了作为嘌呤受体1的配体的化合物，有些实施例中还提供了对其的调节剂（例如，激动剂）。
• [EN] COMPOUNDS FOR USE AS PAIN THERAPEUTICS<br/>[FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QU'AGENTS THÉRAPEUTIQUES CONTRE LA DOULEUR
  申请人：LEDERMAN SETH

  公开号：WO2016105449A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibromyalgia-ness; central sensitization; centralization; regional pain syndrome; temporomandibular joint syndrome (TMJ); lower back pain; interstitial cystitis; Gulf War syndrome; visceral pain; phantom limb painj.kidney stones; gout; neuropathic pain; post-herpetic neuralgia; diabetic neuropathy; sickle cell pain; priapism; nociceptive pain; post-operative pain; orthopedic injury pain; bunionectomy; dental extraction; pain after severed spinal cord injury; osteoarthritis; rheumatoid arthritis; Lyme disease; Parkinson's disease; opioid-induced constipation; an opioid withdrawal symptom; pain associated with post-traumatic stress disorder (PTSD); and combinations of any of the foregoing conditions. This disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了用作镇痛剂和用于治疗以下一种或多种疾病的化合物和组合物：疼痛；心理疼痛；心理疼痛；精神疼痛；抑郁症；痛觉过敏；纤维肌痛；纤维肌痛症；中枢敏感化；中枢化；区域性疼痛综合征；颞下颌关节综合征（TMJ）；腰部疼痛；间质性膀胱炎；海湾战争综合征；内脏疼痛；幻肢疼痛；肾结石；痛风；神经性疼痛；带状疱疹后神经痛；糖尿病性神经病；镰状细胞疼痛；阴茎长时间勃起症；伤害性疼痛；术后疼痛；骨科损伤疼痛；拇外翻术；牙科拔牙；断裂脊髓损伤后疼痛；骨关节炎；类风湿关节炎；莱姆病；帕金森病；阿片类药物引起的便秘；阿片类药物戒断症状；与创伤后应激障碍（PTSD）相关的疼痛；以及上述任何疾病的组合。本公开还提供了作为咪唑啉受体类型1的配体的化合物，有些实施例中是调节剂（例如，激动剂）。
• Phenoxymethyl imidazoline derivatives and their use as pesticides
  申请人：Syngenta Participations AG

  公开号：EP1958508A1

  公开（公告）日：2008-08-20

  The present invention relates to imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. In particular the present invention relates to imidazolines with alkyl and fluoro substituents.

  本发明涉及咪唑啉衍生物及其作为杀虫、杀螨、杀软体动物和杀线虫剂的用途。该发明还涉及包含这些咪唑啉衍生物的杀虫、杀螨、杀软体动物和杀线虫组合物，以及使用这些衍生物和/或组合物来对抗和控制昆虫、螨虫、软体动物和线虫害的方法。具体来说，本发明涉及具有烷基和氟取代基的咪唑啉。
• HALOSUBSTITUTED ARYLOXYALKYLIMIDAZOLINES FOR USE AS PESTICIDES
  申请人：Luethy Christoph

  公开号：US20100280088A1

  公开（公告）日：2010-11-04

  The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. A compound of formula (I) and salts and N-oxides thereof, wherein: R 1 is C 1-10 alkyl; R 2 is chloro, bromo or iodo; R 3 is C 2-5 alkyl, C 1-5 haloalkyl, C 1-6 hydroxyalkyl, C 1-5 alkoxy-(C 1-3 )-alkyl, di-(C 1-5 alkoxy)-(C 1-3 )-alkyl, C 1-5 alkylthio-(C 1-3 )-alkyl; C 1-5 alkylsulfinyl-(C 1-3 )alkyl; C 2-5 alkenyl, C 1-5 haloalkenyl, C 2-5 alkinyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, hydroxy, C 1-5 alkoxy, C 1-5 haloalkoxy, C 1-5 alkylthio, C 1-5 haloalkylthio, formyl, cyano, bromo, or iodo; Z is hydrogen, hydroxy, nitro cyano, rhodano, formyl, G-, G-S—, G-S—S—, G-A-, R 7 R 8 N—, R 7 R 8 N—S—, R 7 R 8 N-A-, G-O-A-, G-S-A-, (R 10 O)(R 11 O)P(X)—, (R 10 O)(R 11 S)P(X)—, (R 10 O)(R 11 )P(X)—, (R 10 S)(R 11 S)P(X)—, (R 10 O)(R 14 R 15 N)P(X)—, (R 11 )(R 14 R 15 N)P(X)—, (R 14 R 15 N)(R 16 R 17 N)P(X)—, G-N═CH—, G-O—N═CH—, N≡C—N═CH—, or Z is a group of formula (II), wherein B is S—, S—S—, S(O)—, C(O)—, or (CH 2 ) n —; n is an integer from 1 to 6; and R 1 , R 2 , and R 3 are as defined above; and G is optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted C 3-7 cycloalkyl, optionally substituted C 3-7 cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; A is S(O), SO 2 , C(O) or C(S).

  本发明涉及新型咪唑啉衍生物及其作为杀虫、杀螨、杀软体动物和杀线虫剂的用途。该发明还扩展到包含这种咪唑啉衍生物的杀虫、杀螨、杀软体动物和杀线虫组合物，以及使用这种衍生物和/或组合物对昆虫、螨虫、软体动物和线虫害进行打击和控制的方法。式（I）的化合物及其盐和N-氧化物，其中：R1为C1-10烷基；R2为氯、溴或碘；R3为C2-5烷基、C1-5卤代烷基、C1-6羟基烷基、C1-5烷氧-(C1-3)-烷基、二-(C1-5烷氧)-(C1-3)-烷基、C1-5烷基硫醇-(C1-3)-烷基；C1-5烷基亚砜基-(C1-3)烷基；C2-5烯基、C1-5卤代烯基、C2-5炔基、C3-6环烷基、C3-6环烯基、羟基、C1-5烷氧基、C1-5卤代烷氧基、C1-5烷基硫基、C1-5卤代烷基硫基、甲酰基、氰基、溴基或碘基；Z为氢、羟基、硝基、氰基、硫氰酸根、甲酰基、G-、G-S—、G-S—S—、G-A-、R7R8N—、R7R8N—S—、R7R8N-A-、G-O-A-、G-S-A-、(R10O)(R11O)P(X)—、(R10O)(R11S)P(X)—、(R10O)(R11)P(X)—、(R10S)(R11S)P(X)—、(R10O)(R14R15N)P(X)—、(R11)(R14R15N)P(X)—、(R14R15N)(R16R17N)P(X)—、G-N═CH—、G-O—N═CH—、N≡C—N═CH—，或Z为式（II）的基团，其中B为S—、S—S—、S(O)—、C(O)—或(CH2)n—；n为1到6的整数；R1、R2和R3如上所定义；G是可选的取代C1-10烷基、可选的取代C2-10烯基、可选的取代C2-10炔基、可选的取代C3-7环烷基、可选的取代C3-7环烯基、可选的取代芳基、可选的取代杂芳基或可选的取代杂环烷基；A为S(O)、SO2、C(O)或C(S)。